Danaher Co. (NYSE:DHR) Stock Position Cut by Central Bank & Trust Co.

Central Bank & Trust Co. trimmed its stake in shares of Danaher Co. (NYSE:DHR) by 0.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,308 shares of the conglomerate’s stock after selling 69 shares during the quarter. Central Bank & Trust Co.’s holdings in Danaher were worth $2,032,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in Danaher by 7.4% in the first quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock worth $15,009,928,000 after purchasing an additional 4,163,657 shares during the period. Swedbank AB bought a new position in Danaher during the first quarter valued at about $676,545,000. TD Asset Management Inc grew its holdings in Danaher by 99.0% during the second quarter. TD Asset Management Inc now owns 1,358,706 shares of the conglomerate’s stock worth $339,473,000 after acquiring an additional 675,952 shares during the period. Massachusetts Financial Services Co. MA raised its position in Danaher by 22.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 3,047,728 shares of the conglomerate’s stock worth $761,475,000 after acquiring an additional 563,546 shares in the last quarter. Finally, International Assets Investment Management LLC lifted its holdings in Danaher by 40,196.5% in the 3rd quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock valued at $119,539,000 after acquiring an additional 428,897 shares during the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Danaher

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 10.90% of the stock is currently owned by corporate insiders.

Danaher Price Performance

NYSE DHR opened at $247.18 on Tuesday. The firm has a market cap of $178.53 billion, a P/E ratio of 47.17, a price-to-earnings-growth ratio of 4.55 and a beta of 0.85. The stock’s 50-day moving average is $266.53 and its two-hundred day moving average is $260.74. Danaher Co. has a fifty-two week low of $192.35 and a fifty-two week high of $281.70. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same period in the previous year, the company earned $2.02 EPS. The company’s revenue for the quarter was up 3.1% on a year-over-year basis. On average, analysts anticipate that Danaher Co. will post 7.51 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were given a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. The ex-dividend date of this dividend was Friday, September 27th. Danaher’s dividend payout ratio is currently 20.61%.

Analyst Ratings Changes

DHR has been the topic of a number of research reports. Leerink Partners boosted their target price on shares of Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. Barclays dropped their price target on Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 23rd. KeyCorp raised their price objective on Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. Raymond James cut their target price on Danaher from $310.00 to $300.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Finally, TD Cowen lifted their price target on Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to data from MarketBeat, Danaher has an average rating of “Moderate Buy” and a consensus price target of $287.16.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.